NASDAQ:ATAI Atai Life Sciences (ATAI) Stock Price, News & Analysis $1.50 +0.03 (+2.04%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.48 -0.02 (-1.33%) As of 05/2/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Atai Life Sciences Stock (NASDAQ:ATAI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Atai Life Sciences alerts:Sign Up Key Stats Today's Range$1.49▼$1.5450-Day Range$1.21▼$1.7352-Week Range$1.03▼$2.57Volume1.56 million shsAverage Volume1.51 million shsMarket Capitalization$299.69 millionP/E RatioN/ADividend YieldN/APrice Target$10.50Consensus RatingBuy Company OverviewAtai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Read More… Atai Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreATAI MarketRank™: Atai Life Sciences scored higher than 40% of companies evaluated by MarketBeat, and ranked 432nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAtai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtai Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Atai Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Atai Life Sciences are expected to grow in the coming year, from ($0.77) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atai Life Sciences is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atai Life Sciences is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtai Life Sciences has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atai Life Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.91% of the float of Atai Life Sciences has been sold short.Short Interest Ratio / Days to CoverAtai Life Sciences has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Atai Life Sciences has recently increased by 3.94%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtai Life Sciences does not currently pay a dividend.Dividend GrowthAtai Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.91% of the float of Atai Life Sciences has been sold short.Short Interest Ratio / Days to CoverAtai Life Sciences has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Atai Life Sciences has recently increased by 3.94%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 3 people have searched for ATAI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Atai Life Sciences insiders have bought 20,428.49% more of their company's stock than they have sold. Specifically, they have bought $22,755,008.00 in company stock and sold $110,846.00 in company stock.Percentage Held by Insiders31.20% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.41% of the stock of Atai Life Sciences is held by institutions.Read more about Atai Life Sciences' insider trading history. Receive ATAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ATAI Stock News HeadlinesAtai Life Sciences: Pipeline And Regulatory Uncertainties Warrant Hold RatingApril 21, 2025 | seekingalpha.comAtai Life Sciences initiated with a Positive at BerenbergApril 5, 2025 | markets.businessinsider.comVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.May 3, 2025 | Stansberry Research (Ad)Is Atai Life Sciences (ATAI) the Best German Stock to Buy According to Hedge Funds?April 2, 2025 | insidermonkey.comatai Life Sciences CEO discusses major data readouts expected through 2025 - ICYMIMarch 29, 2025 | proactiveinvestors.comInsiders Make Huge Purchases of These 4 Biotech StocksMarch 26, 2025 | 247wallst.com Biopharma exec says Bitcoin could help industry through ‘biotech winter’ March 21, 2025 | cointelegraph.comPsychedelic: atai Life Sciences, NRx report quarterly resultsMarch 21, 2025 | markets.businessinsider.comSee More Headlines ATAI Stock Analysis - Frequently Asked Questions How have ATAI shares performed this year? Atai Life Sciences' stock was trading at $1.33 at the beginning of 2025. Since then, ATAI stock has increased by 12.8% and is now trading at $1.50. View the best growth stocks for 2025 here. How were Atai Life Sciences' earnings last quarter? Atai Life Sciences (NASDAQ:ATAI) posted its quarterly earnings results on Monday, March, 17th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.10. The business earned ($0.01) million during the quarter, compared to analyst estimates of $0.30 million. When did Atai Life Sciences IPO? Atai Life Sciences (ATAI) raised $200 million in an initial public offering on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers. Who are Atai Life Sciences' major shareholders? Top institutional shareholders of Atai Life Sciences include Capital Advisors Inc. OK (0.04%), Kingswood Wealth Advisors LLC (0.04%) and Regent Peak Wealth Advisors LLC (0.01%). Insiders that own company stock include Apeiron Investment Group Ltd, Life Sciences NV Atai, Florian Brand, Anne Nagengast Johnson, Sahil Kirpekar and Srinivas Rao. View institutional ownership trends. How do I buy shares of Atai Life Sciences? Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atai Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atai Life Sciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings3/17/2025Today5/03/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATAI CIK1420529 Webwww.atai.net.cn Phone49-89-2153-9035FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$10.50 High Stock Price Target$11.00 Low Stock Price Target$10.00 Potential Upside/Downside+600.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,220,000.00 Net MarginsN/A Pretax Margin-38,531.72% Return on Equity-65.75% Return on Assets-52.71% Debt Debt-to-Equity Ratio0.14 Current Ratio5.81 Quick Ratio5.81 Sales & Book Value Annual Sales$308,000.00 Price / Sales973.03 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book1.02Miscellaneous Outstanding Shares199,795,000Free Float115,448,000Market Cap$299.69 million OptionableOptionable Beta1.24 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:ATAI) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.